摘要
目的探讨厄洛替尼一线化疗方案对于老年中晚期非小细胞肺癌患者的临床疗效及安全性。方法对收治78例老年中晚期非小细胞肺癌患者,随机分为实验组和对照组。实验组患者给予厄洛替尼化疗,对照组给予紫杉醇化疗。比较两组患者治疗的有效率、疾病控制率、无进展生存期、总生存期以及不良反应的发生情况。结果实验组患者有效率、疾病控制率、无进展生存期、总生存期分别为28.2%、76.9%、(168.3±21.4)d、(287.7±39.3)d,对照组患者为20.5%、74.4%(149.23±19.7)d、(243.7±12.6)d,实验组有效率、无进展生存期、总生存期显著高于对照组(P<0.05),两组疾病控制率无显著差别(P>0.05)。结论厄洛替尼一线化疗方案对于不愿接受传统化疗的老年中晚期非小细胞肺癌患者疗效显著,且不良反应可以耐受。
Objective To investigate the clinical efficacy and safety of erlotinib as first-line chemotherapy for elderly patients with advanced non-small cell lung cancer. Methods 78 elderly patients with advanced non-small cell lung cancer in our hospital were ran- domly divided into the experimental group and the control group. The experimental group were treated with erlotinib as first-line chemo- therapy, and the control group were given paelitaxcl chemotherapy. Results The effective rate, disease control rate, progression-free sur- vival time, overall survival time of patients in the experimental group were respectively 28.2%, 76. 9%, 168.3 ±21.4 days, 287.7 ±39.3 days, while the correspondent data of patients in the control group were 20. 5%, 74. 4%, 149.2.3±19.7 days, 243.7 ± 12. 6days. Response rate, progression-free survival time, overall survival time of the experimental group were significantly higher than those of the control group （ P 〈 0. 05 ）, and there was no significant difference in disease control rate between the two groups （ P 〉 0. 05 ）. Conclu- sion Erlotinib as first-line chemotherapy has a significant effect on elderly patients with advanced non-small cell lung cancer who are un- willing to accept the traditional chemotherapy, and its adverse reactions can be tolerated, which is worth to be applied clinically.
出处
《临床肺科杂志》
2013年第3期392-394,共3页
Journal of Clinical Pulmonary Medicine
关键词
厄洛替尼
老年
非小细胞肺癌
疗效分析
erlotinib
elderly
non-small cell lung cancer
efficacy analysis
